** Shares of biotech firm Immunic IMUX.O down 12% to 80 cents in extended trading as it looks to raise equity
** New York -based IMUX announces public offering of pre-funded warrants and warrants to purchase shares; deal not disclosed
** Co intends to use net proceeds to fund clinical trials and operations and other general purposes
** Co says its lead drug, vidofludimus calcium (IMU-838), currently in phase III trials for treatment of relapsing multiple sclerosis, for which top-line data is expected to be available end of 2026
** Multiple sclerosis is a chronic autoimmune disease that affects the central nervous system
** Leerink sole bookrunner for proposed offering
** With ~95.8 mln shares outstanding as of May 14, per the SEC prospectus filing, giving IMUX ~$87 mln market cap
** IMUX shares on Weds rose 2 cents to close at 91 cents. Stock hit 52-week high of $2.11 in Sept
(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper@tr.com 1-646-279-6380))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.